<div id="readability-page-1">Strategic Blueprint LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 84.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,374 shares of the medical research company's stock after selling 7,306 shares during the period. Strategic Blueprint LLC's holdings in Amgen were worth $450,000 at the end of the most recent quarter.<ul><li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li></ul>Other institutional investors and hedge funds also recently bought and sold shares of the company. Board of the Pension Protection Fund purchased a new position in Amgen during the fourth quarter valued at $26,000. Olistico Wealth LLC purchased a new position in Amgen during the fourth quarter valued at $33,000. Cloud Capital Management LLC purchased a new position in Amgen during the third quarter valued at $34,000. Ares Financial Consulting LLC purchased a new position in Amgen during the fourth quarter valued at $34,000. Finally, Saranac Partners Ltd purchased a new position in Amgen during the third quarter valued at $37,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors. <h2>Amgen Price Performance</h2>Shares of Amgen stock opened at $346.25 on Friday. The stock's 50-day simple moving average is $358.07 and its 200-day simple moving average is $340.45. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a market capitalization of $186.86 billion, a price-to-earnings ratio of 24.33, a PEG ratio of 3.34 and a beta of 0.47. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. <ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul>Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.73 by $0.42. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the business earned $4.90 earnings per share. The business's revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts expect that Amgen Inc. will post 22.16 earnings per share for the current fiscal year. <h2>Amgen Announces Dividend</h2>The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen's payout ratio is currently 70.84%. <h2>Analyst Upgrades and Downgrades</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul>Several equities analysts recently weighed in on the company. Daiwa Securities Group lifted their target price on Amgen from $370.00 to $410.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, February 10th. Jefferies Financial Group assumed coverage on Amgen in a research report on Tuesday, March 10th. They set a &#34;hold&#34; rating and a $350.00 target price on the stock. UBS Group lifted their target price on Amgen from $390.00 to $400.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, April 13th. Oppenheimer set a $400.00 price objective on Amgen and gave the company an &#34;outperform&#34; rating in a research report on Thursday, January 29th. Finally, Wall Street Zen downgraded Amgen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, April 25th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and an average target price of $356.62.Check Out Our Latest Analysis on AMGN<h2>More Amgen News</h2>Here are the key news stories impacting Amgen this week:<ul> <li>Positive Sentiment: Q1 results: Amgen reported EPS of $5.15 vs. consensus ~$4.74 and revenue of $8.62B vs. ~$8.58B — beats on both lines and sales rose ~4%, supporting the near‑term earnings story. Amgen’s NASDAQ: AMGN Q1 CY2026 sales top estimates</li> <li>Positive Sentiment: Mgmt commentary/slides: Management framed 2026 as a “springboard” year and highlighted six growth drivers; investors may take this as confidence in product mix and pipeline execution. Amgen (AMGN) Q1 2026 Earnings Transcript</li> <li>Positive Sentiment: Pipeline progress: Amgen is advancing a broader development program for weight‑loss candidate MariTide and submitted a label update to the FDA for an autoimmune drug — signs of R&amp;D activity that could drive medium‑term growth. Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug</li> <li>Neutral Sentiment: Guidance: FY‑2026 EPS guidance set to 21.700–23.100 (consensus ~22.29); revenue guidance $37.1B–$38.5B (consensus ~37.8B) — range leaves room for beats or misses, which could sustain volatility as analysts model the year. Amgen Q1 press release and slide deck</li> <li>Neutral Sentiment: Analyst sentiment: Wall Street remains moderately optimistic on targets but Amgen has underperformed the market over the past year — analysts will reassess models after the quarter. What Are Wall Street Analysts' Target Price for Amgen Stock?</li> <li>Negative Sentiment: Tavneos regulatory risk: An FDA advisory panel raised efficacy/data concerns for Tavneos and there have been reports of a proposed U.S. withdrawal — this is a material downside catalyst for a rare‑disease franchise and could pressure sentiment until resolved. Amgen faces U.S. withdrawal of rare disorder therapy Tavneos</li> </ul><h2>About Amgen</h2> (Free Report)Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients. Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.<h2>Featured Articles</h2><ul><li>Five stocks we like better than Amgen</li></ul><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Amgen Right Now?</h2>Before you consider Amgen, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

AMGN

ARKG

Strategic Blueprint LLC has reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 84.2% in the fourth quarter, now holding 1,374 shares valued at $450,000. Other institutional investors have also made new purchases in Amgen. The stock opened at $346.25, with a market cap of $186.86 billion and a P/E ratio of 24.33. Amgen reported Q1 earnings of $5.15 EPS, exceeding estimates, and announced a quarterly dividend of $2.52. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average target price of $356.62.

Market Beat

Amgen

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

SPDR S&P Biotech

iShares Global Healthcare

Daiwa Securities Group Inc.

Jefferies Financial

UBS Group AG

Oppenheimer

Strategic Blueprint LLC Lowers Position in Amgen Inc. $AMGN